Merck KGaA expects 2023 to be a challenging year but is hoping that two relatively recently launched drugs – Mavenclad and Bavencio – will continue to grow while it awaits two late-stage assets to progress through the clinic.
Merck KGaA Expects Modest Growth Ahead Of Launches Next Year
High Hopes For Xenipant And Evobrutinib
The German firm is eyeing licensing opportunities in 2023 to fill up its mid-stage pipeline.
